These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 16133649

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.
    Ström O, Borgström F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA.
    Osteoporos Int; 2007 Aug; 18(8):1047-61. PubMed ID: 17333449
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
    Mori T, Crandall CJ, Ganz DA.
    Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.
    Schousboe JT, Nyman JA, Kane RL, Ensrud KE.
    Ann Intern Med; 2005 May 03; 142(9):734-41. PubMed ID: 15867405
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.
    Health Technol Assess; 2005 Jun 03; 9(22):1-160. PubMed ID: 15929857
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
    Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, Melton LJ, Bauer DC, Ensrud KE.
    JAMA; 2007 Aug 08; 298(6):629-37. PubMed ID: 17684185
    [Abstract] [Full Text] [Related]

  • 12. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004 Aug 08; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
    Yoshizawa T, Nishino T, Okubo I, Yamazaki M.
    Arch Osteoporos; 2018 Aug 29; 13(1):94. PubMed ID: 30159632
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
    Moriwaki K, Fukuda H.
    Osteoporos Int; 2019 Feb 29; 30(2):299-310. PubMed ID: 30610244
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
    Hiligsmann M, Reginster JY.
    Pharmacoeconomics; 2011 Oct 29; 29(10):895-911. PubMed ID: 21692551
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
    Mueller D, Gandjour A.
    Appl Health Econ Health Policy; 2008 Oct 29; 6(2-3):113-35. PubMed ID: 19231905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.